Longeveron Executes 1-for-10 Reverse Stock Split to Meet Nasdaq Listing Requirements — Longeveron Inc.

Event summary

Longeveron will implement a 1-for-10 reverse stock split effective August 26, 2026, with trading on a split-adjusted basis beginning August 27, 2026.
The reverse split reduces outstanding Class A shares from ~30.4 million to ~3.04 million and Class B shares from ~1.45 million to ~144,901.
The move aims to meet Nasdaq's $1.00 minimum bid price requirement for continued listing.
No fractional shares will be issued; fractional shares will be rounded up to the nearest whole share at the DTC participant level.
The company's CEO cited alignment with institutional investor preferences as a secondary motivation.

The big picture

Longeveron's reverse stock split is a strategic maneuver to comply with Nasdaq's listing requirements, a common move for biotech companies facing share price pressures. The adjustment also signals an attempt to align with institutional investor preferences, potentially broadening the company's ownership base. This comes as Longeveron approaches critical milestones in its stem cell therapy development programs, which could redefine its business trajectory.

What we're watching

Regulatory Compliance: Whether the reverse split will successfully maintain Longeveron's listing on Nasdaq and avoid further regulatory scrutiny.
Investor Sentiment: How institutional investors will react to the structural change and whether it attracts new investors.
Operational Milestones: The pace at which Longeveron can achieve its upcoming transformative milestones across its four stem cell therapy programs.